Company’s major investment company announces filing of protection for proprietary method of THC extraction that will achieve highest THC purity level on the market.
SAN DIEGO – Nov. 29, 2016 – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) has filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods being used in the market today.
THC is the most commonly known cannabinoid derived from the cannabis plant. The recently-filed IP would give protection to the invention of a method of extraction of THC-A from cannabis flower using a solvent where the yield is approximately 50 – 70% with regards to THC-A content in the starting material. A neutral metal salt or inorganic base solution saturated with the metal neutral salt and adjusted to basic pH enables separation of the THC-A layer and significantly increases the yield. THC-A is then decarboxylated in a water/ethanol solution to render THC at a purity greater than 95%.
The IP was generated in collaboration with Syncom B.V., a Netherlands-based premier company in custom synthesis solutions for pharmaceutical and biotech industry.
“We are extremely excited to see that AXIM has filed this IP it as it represents the first stage of a chain of processes in development of novel and revolutionary drug products all based on AXIM’s propriety IP,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “This is another example of how AXIM is at the forefront of the cannabis biotechnology industry. This extraction method will change how THC can be utilized in products in the future and open up new possibilities for the industry as a whole.”
He continued, “The THC purity level that AXIM is able to achieve through this invention will untimely represent a milestone achievement in the standardizing of cannabis based products. With roughly 440 marijuana strains in existence with varying levels of cannabinoids, trying to make this into a standardized medicine has represented a real challenge for the research community. Now AXIM has overcome these hurdles and we believe this will allow for future cannabis based drug development opportunities.”
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]